ArticleJournal of medical virology2026
Neonatal CNS Human Parechovirus Infections in Western Pennsylvania in the 2024 Season.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human Parechovirus A (PeV-A) is a virus with near-universal infection by age five; however, neonatal infections can lead to meningoencephalitis, sepsis, and death. Prior to the COVID-19 pandemic, PeV-A showed biennial seasonality with late summer peaks, but multiple viruses have had shifted circulation post-pandemic. PeV-A is not universally included in neonatal sepsis testing; thus, the frequency and clinical spectrum of PeV-A neonatal meningoencephalitis are not fully described. We sought to evaluate the epidemiology, seasonality, and clinical presentation of neonatal PeV-A in the 2024 season. We collected remnant cerebrospinal fluid samples from febrile infants under 60 days at a single children's hospital in Southwestern Pennsylvania and assessed for PeV-A and enterovirus (EV). Six out of 107 (5.6%) febrile infants were positive for PeV-A and 24 (22.4%) were positive for EV. PeV-A infections occurred from June to September. PeV-A positive patients had a distinct combination of higher maximum temperature, rash, and leukopenia without pleocytosis. None of these infants had severe disease. Systematic surveillance of PeV-A is required to completely understand ongoing PeV-A circulation patterns, expected clinical course, and long-term developmental implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.